Patent

Novartis AG and others v Focus pharmaceuticals Ltd and others; Novartis AG and others v Teva UK Ltd [2015] EWHC 1068 (Pat), [2015] All ER (D) 233 (Apr)

The Patents Court considered a claim for infringement of European Patent (UK) No 2 292 219 directed to the use of rivastigmine for use in the treatment of Alzheimer’s disease wherein the rivastigmine was administered by a transdermal therapeutic system. The court held that the patent was invalid on the ground of added matter and since the claimed invention lacked an inventive step over a previous patent.

If you are not a subscriber, subscribe now to read this content

If you are already a subscriber sign in

...or Register for two weeks' free access to subscriber content

E-newsletter Sign-Up

MOVERS & SHAKERS

Read All

Clarke Willmott—Matthew Roach

Partner joins commercial property team in Taunton office

Farrer & Co—Richard Lane

Londstanding London firm appoints new senior partner

Bird & Bird—Sue McLean

Commercial team in London welcomes technology specialist as partner

NEWS

Read All

NLJ this week: Is inequality undermining trust?

The legal profession’s claim to be a ‘guardian of fairness’ is under scrutiny after stark findings on gender imbalance and opaque progression. Writing in NLJ this week, Joshua Purser of No5 Barristers’ Chambers and Govindi Deerasinghe of Global 50/50 warn that leadership remains dominated by a narrow elite, with men holding 71% of top court roles

NLJ this week: Freemasons ruling backs police transparency over privacy claims

A legal challenge to police disclosure rules has failed, reinforcing a push for transparency in policing. In NLJ this week, Neil Parpworth examines a case where the Metropolitan Police required officers to declare membership of groups like the Freemasons

NLJ this week: Right to grieve marks ‘major shift’ in employment law

Bereavement leave is undergoing a quiet but profound transformation. Writing in NLJ this week, Robert Hargreaves of York St John University explains how the Employment Rights Act 2025 introduces a day-one right to leave for a wider range of losses, alongside new provisions for pregnancy loss and bereaved partners

NLJ this week: AI privilege battles expose risks

Courts are beginning to grapple with whether AI-generated material is legally privileged—and the answers are mixed. In this week's issue of NLJ, Stacie Bourton, Tom Whittaker & Beata Kolodziej of Burges Salmon examine US rulings showing how easily privilege can be lost

NLJ this week: Experts warned—AI use must be transparent

New guidance seeks to bring order to the growing use of artificial intelligence (AI) in expert evidence. Writing in NLJ this week, Minesh Tanna and David Bridge of Simmons & Simmons set out a framework stressing ‘transparency’, ‘explainability’ and ‘reliability’

Error message

Patent

MOVERS & SHAKERS

Clarke Willmott—Matthew Roach

Farrer & Co—Richard Lane

Bird & Bird—Sue McLean